ATE513905T1 - Verfahren für die replikation von influenza in zellkultur, und die bei diesem verfahren hergestellten influenza viren - Google Patents

Verfahren für die replikation von influenza in zellkultur, und die bei diesem verfahren hergestellten influenza viren

Info

Publication number
ATE513905T1
ATE513905T1 AT05075182T AT05075182T ATE513905T1 AT E513905 T1 ATE513905 T1 AT E513905T1 AT 05075182 T AT05075182 T AT 05075182T AT 05075182 T AT05075182 T AT 05075182T AT E513905 T1 ATE513905 T1 AT E513905T1
Authority
AT
Austria
Prior art keywords
influenza
replication
cell culture
influenza viruses
viruses produced
Prior art date
Application number
AT05075182T
Other languages
English (en)
Inventor
Albrecht Groner
Juergen Vorlop
Original Assignee
Novartis Vaccines & Diagnostic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7790127&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE513905(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic
Application granted granted Critical
Publication of ATE513905T1 publication Critical patent/ATE513905T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT05075182T 1996-04-01 1997-04-01 Verfahren für die replikation von influenza in zellkultur, und die bei diesem verfahren hergestellten influenza viren ATE513905T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19612967A DE19612967A1 (de) 1996-04-01 1996-04-01 Verfahren zur Vermehrung von Influenzaviren in Zellkultur, sowie die durch das Verfahren erhältlichen Influenzaviren

Publications (1)

Publication Number Publication Date
ATE513905T1 true ATE513905T1 (de) 2011-07-15

Family

ID=7790127

Family Applications (2)

Application Number Title Priority Date Filing Date
AT05075182T ATE513905T1 (de) 1996-04-01 1997-04-01 Verfahren für die replikation von influenza in zellkultur, und die bei diesem verfahren hergestellten influenza viren
AT97915628T ATE288479T1 (de) 1996-04-01 1997-04-01 Verfahren fuer die replikation von influenza in zellkultur und die bei diesem verfahren hergestellten influenza-viren

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT97915628T ATE288479T1 (de) 1996-04-01 1997-04-01 Verfahren fuer die replikation von influenza in zellkultur und die bei diesem verfahren hergestellten influenza-viren

Country Status (13)

Country Link
US (2) US20030119183A1 (de)
EP (3) EP1526172B1 (de)
JP (6) JP4447054B2 (de)
AT (2) ATE513905T1 (de)
CA (1) CA2250078C (de)
DE (3) DE19612967A1 (de)
DK (2) DK1526172T3 (de)
ES (3) ES2435726T3 (de)
HK (2) HK1075467A1 (de)
LU (1) LU91381I2 (de)
NL (1) NL300307I1 (de)
PT (2) PT1526172E (de)
WO (1) WO1997037001A1 (de)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19612966B4 (de) 1996-04-01 2009-12-10 Novartis Vaccines And Diagnostics Gmbh & Co. Kg MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren
CA2307832C (en) * 1997-10-31 2005-09-06 Merck & Co., Inc. A method of improved mixing of a varicella-infected cell culture in roller bottles
WO1999023204A1 (en) * 1997-10-31 1999-05-14 Merck & Co., Inc. A method of improved mixing in roller bottles
FR2775601B1 (fr) * 1998-03-03 2001-09-21 Merial Sas Vaccins vivants recombines et adjuves
ATE473272T1 (de) 2000-03-03 2010-07-15 Chemo Sero Therapeut Res Inst In serumfreier kultur verwendbare zelle, kultursuspension und verfahren zur virusproduktion als impfstoff unter verwendung der zelle
DE10144906B4 (de) * 2001-09-12 2013-11-28 Novartis Vaccines And Diagnostics Gmbh Verfahren zur großtechnischen Herstellung von Impfstoffen
AU2002366267B2 (en) * 2001-11-19 2007-05-10 Becton, Dickinson And Company Pharmaceutical compositions in particulate form
DE50211264D1 (de) * 2002-09-16 2008-01-03 Pan Biotech Gmbh Einrichtung zur kultivierung von zellen, insbesondere menschlicher oder tierischer zellen
WO2004033615A1 (de) 2002-09-16 2004-04-22 Pan-Biotech Gmbh Verfahren zur kultivierung von zellen, insbesondere menschlicher oder tierischer zellen
DE602004028736D1 (de) 2003-06-20 2010-09-30 Microbix Biosystems Inc Verbesserungen bei der virusproduktion
CA2559371C (en) 2004-03-09 2014-07-08 Chiron Corporation Influenza virus vaccines
EP1747268A1 (de) * 2004-05-20 2007-01-31 ID Biomedical Corporation Verfahren zur herstellung einer influenzavakzine
EP1766034B1 (de) 2004-05-21 2014-03-19 Novartis Vaccines and Diagnostics, Inc. Alphavirus-vektoren für impfstoffe gegen das influenza virus
WO2006027698A1 (en) * 2004-09-09 2006-03-16 Novartis Vaccines And Diagnostics Gmbh & Co Kg. Decreasing potential iatrogenic risks associated with influenza vaccines
JP5085336B2 (ja) 2004-12-08 2012-11-28 メディミューン，エルエルシー インフルエンザワクチン組成物の製造方法
KR101323459B1 (ko) 2004-12-23 2013-10-29 메디뮨 엘엘씨 바이러스의 증식을 위한 비종양형성성 ｍｄｃｋ 세포주
FR2884255B1 (fr) 2005-04-11 2010-11-05 Vivalis Utilisation de lignees de cellules souches aviaires ebx pour la production de vaccin contre la grippe
CN104474543A (zh) 2005-11-01 2015-04-01 诺华疫苗和诊断有限两合公司 经由β-丙内酯处理的残留细胞DNA水平降低的细胞衍生病毒疫苗
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
KR20080069232A (ko) 2005-11-04 2008-07-25 노바티스 백신즈 앤드 다이아그노스틱스 에스.알.엘. 스플리트 인플루엔자 백신에 대한 보조제로서 유리 수성상계면활성제를 갖는 에멀젼
EP2368572B1 (de) * 2005-11-04 2020-03-04 Seqirus UK Limited Adjuvansimpfstoffe mit nicht virenähnlichen Antigenen aus Influenza-Viren, die in einer Zellkultur gezüchtet wurden
NZ568211A (en) 2005-11-04 2011-11-25 Novartis Vaccines & Diagnostic Influenza vaccines including combinations of particulate adjuvants and immunopotentiators
JP2009514850A (ja) 2005-11-04 2009-04-09 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル アジュバントとして減少した量の水中油型エマルションを有するインフルエンザワクチン
NZ592713A (en) 2005-11-04 2012-12-21 Novartis Vaccines & Diagnostic Adjuvanted influenza vaccines including a cytokine-inducing agents other than an agonist of Toll-Like Receptor 9
KR20110110853A (ko) 2006-01-27 2011-10-07 노파르티스 파르마 아게 적혈구응집소 및 기질 단백질을 함유한 인플루엔자 백신
US20100068223A1 (en) 2006-03-24 2010-03-18 Hanno Scheffczik Storage of Influenza Vaccines Without Refrigeration
AU2007245192B2 (en) 2006-03-31 2012-04-12 Wisconsin Alumni Research Foundation High titer recombinant influenza viruses for vaccines
EP2022849A4 (de) * 2006-05-11 2010-10-06 Chemo Sero Therapeut Res Inst Verfahren zur proliferation von influenzavirus
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
CA3016948A1 (en) 2006-09-11 2008-03-20 Seqirus UK Limited Making influenza virus vaccines without using eggs
SG174813A1 (en) 2006-09-15 2011-10-28 Medimmune Llc Mdck cell lines supporting viral growth to high titers and bioreactor process using the same
PL2121011T3 (pl) 2006-12-06 2014-10-31 Novartis Ag Szczepionki zawierające antygeny czterech szczepów wirusa grypy
JP5352578B2 (ja) 2007-05-04 2013-11-27 バクスター・インターナショナル・インコーポレイテッド ウイルスの増殖のための二段階温度プロフィール
US9474798B2 (en) 2007-06-18 2016-10-25 Wisconsin Alumni Research Foundation Influenza M2 protein mutant viruses as live influenza attenuated vaccines
EA201070066A1 (ru) 2007-06-27 2010-06-30 Новартис Аг Вакцины против гриппа с низким содержанием добавок
EP2268309B1 (de) 2008-03-18 2015-01-21 Novartis AG Verbesserungen der herstellung von grippevirus-impstoff-antigenen
RU2015103990A (ru) 2008-09-24 2015-10-27 Медиммун, Ллк Способы культивирования клеток, размножения и очистки вирусов
EA201500910A1 (ru) 2009-02-10 2016-04-29 Новартис Аг Вакцины против гриппа со сниженным количеством сквалена
WO2010092477A1 (en) 2009-02-10 2010-08-19 Novartis Ag Influenza vaccines with increased amounts of h3 antigen
CA2752039A1 (en) 2009-02-10 2010-08-19 Novartis Ag Influenza vaccine regimens for pandemic-associated strains
DE102010018462A1 (de) 2009-04-27 2011-04-07 Novartis Ag Impfstoffe zum Schutz gegen Influenza
CN102597246B (zh) 2009-05-21 2014-02-26 诺华股份有限公司 使用非内源pol I启动子的反向遗传
WO2010144797A2 (en) 2009-06-12 2010-12-16 Vaccine Technologies, Incorporated Influenza vaccines with enhanced immunogenicity and uses thereof
EP2459722B1 (de) 2009-07-31 2017-09-06 Seqirus UK Limited Reverse genetiksysteme
CN102695523A (zh) 2009-09-10 2012-09-26 诺华有限公司 针对呼吸道疾病的组合疫苗
CA2778332A1 (en) 2009-10-20 2011-04-28 Novartis Ag Improved reverse genetics methods for virus rescue
ES2813347T3 (es) 2009-10-26 2021-03-23 Wisconsin Alumni Res Found Virus recombinantes de la influenza de alto título con replicación mejorada en células Vero
US20120309056A1 (en) 2010-02-04 2012-12-06 Leon Arnaud Fed-batch process using concentrated cell culture medium for the efficient production of biologics in eb66 cells
US10130697B2 (en) 2010-03-23 2018-11-20 Wisconsin Alumni Research Foundation (Warf) Vaccines comprising mutant attenuated influenza viruses
WO2011139717A1 (en) 2010-04-26 2011-11-10 Novartis Ag Improved production of virus replicon particles in packaging cells
CA2800150C (en) 2010-05-21 2018-09-04 Novartis Ag Influenza virus reassortment method
DK2575872T3 (da) 2010-06-01 2020-10-19 Seqirus Uk Ltd Koncentrering af influenzavaccineantigener uden frysetørring
AU2011262312B2 (en) 2010-06-01 2015-05-28 Novartis Ag Concentration and lyophilization of influenza vaccine antigens
CA2808965C (en) 2010-08-20 2020-01-07 Novartis Ag Soluble needle arrays for delivery of influenza vaccines
WO2012051211A2 (en) 2010-10-11 2012-04-19 Novartis Ag Antigen delivery platforms
PT2667892T (pt) 2011-01-26 2019-06-07 Glaxosmithkline Biologicals Sa Regime de imunização contra o vsr
WO2012122625A1 (en) 2011-03-14 2012-09-20 National Research Council Of Canada Method of viral production in cells
MX2014004214A (es) 2011-10-11 2014-05-07 Novartis Ag Moleculas de acido ribonucleico policistronicas auto-replicantes recombinantes.
EP2766385A2 (de) 2011-10-12 2014-08-20 Novartis AG Cmv-antigene und verwendungen davon
CA2852857A1 (en) 2011-10-20 2013-04-25 Novartis Ag Adjuvanted influenza b virus vaccines for pediatric priming
WO2013087945A2 (en) 2012-03-02 2013-06-20 Novartis Ag Influenza virus reassortment
CA2866465A1 (en) 2012-03-06 2013-09-12 Crucell Holland B.V. Improved vaccination against influenza
JP2015526062A (ja) 2012-06-04 2015-09-10 ノバルティス アーゲー 改善された安全性試験
GB201218195D0 (en) 2012-10-10 2012-11-21 Istituto Zooprofilattico Sperimentale Delle Venezie Composition
WO2014086732A2 (en) 2012-12-03 2014-06-12 Novartis Ag Influenza virus reassortment
MX2015011529A (es) 2013-03-13 2016-02-05 Novartis Ag Reordenamiento del virus de infuenza b.
US20140335116A1 (en) 2013-05-10 2014-11-13 Novartis Ag Avoiding narcolepsy risk in influenza vaccines
DE202013005130U1 (de) 2013-06-05 2013-09-10 Novartis Ag Influenza Virus Reassortierung
DE202013005100U1 (de) 2013-06-05 2013-08-26 Novartis Ag Influenza Virus Reassortierung
WO2014195920A2 (en) 2013-06-06 2014-12-11 Novartis Ag Influenza virus reassortment
EP3022296B1 (de) 2013-07-15 2022-12-28 Wisconsin Alumni Research Foundation Rekombinante influenzaviren mit hohem titer und erhöhter replikation in mdck- oder vero-zellen oder eiern
WO2015196150A2 (en) 2014-06-20 2015-12-23 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to additional genes in influenza viruses
AU2015252119A1 (en) 2014-11-07 2016-05-26 Takeda Vaccines, Inc. Hand, foot, and mouth vaccines and methods of manufacture and use thereof
AR102547A1 (es) 2014-11-07 2017-03-08 Takeda Vaccines Inc Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y su uso
US10633422B2 (en) 2015-06-01 2020-04-28 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication by inhibiting microRNA lec7C binding to influenza viral cRNA and mRNA
JP2018524323A (ja) 2015-06-26 2018-08-30 セキラス ユーケー リミテッド 抗原がマッチしたインフルエンザワクチン
US9890363B2 (en) 2015-07-06 2018-02-13 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication for vaccine development
EP3764098B1 (de) 2015-07-07 2022-11-16 Seqirus UK Limited Influenza-stärke-assays
EP3417056A1 (de) 2016-02-19 2018-12-26 Wisconsin Alumni Research Foundation (WARF) Verbesserte influenza-b-virus-replikation für impfstoffentwicklung
AU2018359556B2 (en) 2017-11-03 2021-12-02 Takeda Vaccines, Inc. Zika vaccines and immunogenic compositions, and methods of using the same
WO2020167432A2 (en) 2019-01-23 2020-08-20 Yoshihiro Kawaoka Mutations that confer genetic stability to additional genes in influenza viruses
CN113874496A (zh) 2019-02-08 2021-12-31 威斯康星校友研究基金会(Warf) 人源化细胞系
US11390649B2 (en) 2019-05-01 2022-07-19 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication for vaccine development
WO2020226831A1 (en) 2019-05-08 2020-11-12 Takeda Vaccines, Inc. Inactivated virus compositions and zika vaccine formulations
EP4022046A2 (de) 2019-08-27 2022-07-06 Wisconsin Alumni Research Foundation (WARF) Rekombinante influenzaviren mit stabilisiertem ha zur replikation in eiern
JP2023502650A (ja) 2019-11-18 2023-01-25 セキラス ピーティーワイ リミテッド 遺伝子再集合インフルエンザウイルスを産生するための方法
KR102444684B1 (ko) * 2020-04-29 2022-09-16 에스케이바이오사이언스(주) 일회용 배양 공정 시스템을 이용한 인플루엔자 바이러스 생산 방법
WO2023154043A1 (en) 2022-02-09 2023-08-17 Takeda Vaccines, Inc. Zika vaccines and immunogenic compositions, and methods of using the same

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1278075B (de) * 1964-06-22 1968-09-19 Norden Lab Inc Verwendung von Gewebekulturen zur Zuechtung von Viren fuer die Gewinnung von Impfstoffen
US4064232A (en) * 1974-01-14 1977-12-20 Sandoz Ltd. Process for isolating the immunogenic components of influenza viruses
US4500513A (en) * 1979-05-15 1985-02-19 Miles Laboratories, Inc. Influenza vaccine production in liquid cell culture
USRE33164E (en) * 1979-05-15 1990-02-13 Mobay Corporation Influenza vaccine production in liquid cell culture
CA1122527A (en) * 1979-05-15 1982-04-27 Karen K. Brown Influenza vaccine production in liquid cell culture
US5013663A (en) * 1983-06-15 1991-05-07 American Home Products Corporation Canine corona virus vaccine
US4783411A (en) * 1984-10-22 1988-11-08 Janis Gabliks Influenza-A virus vaccine from fish cell cultures
US5762939A (en) * 1993-09-13 1998-06-09 Mg-Pmc, Llc Method for producing influenza hemagglutinin multivalent vaccines using baculovirus
US5824536A (en) * 1994-08-23 1998-10-20 St. Jude Children's Research Hospital Influenza virus replicated in mammalian cell culture and vaccine production
US5756341A (en) * 1994-11-10 1998-05-26 Immuno Ag Method for controlling the infectivity of viruses
US5753489A (en) * 1994-11-10 1998-05-19 Immuno Ag Method for producing viruses and vaccines in serum-free culture
US5646033A (en) * 1994-11-30 1997-07-08 Dyncorp African green monkey kidney cell lines useful for maintaining viruses and for preparation of viral vaccines
DE19612966B4 (de) * 1996-04-01 2009-12-10 Novartis Vaccines And Diagnostics Gmbh & Co. Kg MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren
US6514502B1 (en) * 1999-01-26 2003-02-04 Schering-Plough Veterinary Corporation Propagation of bovine cononavirus in chinese hamster ovary cells

Also Published As

Publication number Publication date
ES2236799T3 (es) 2005-07-16
JP2008245659A (ja) 2008-10-16
DE69732407D1 (de) 2005-03-10
WO1997037001A1 (en) 1997-10-09
ATE288479T1 (de) 2005-02-15
DK1526172T3 (da) 2011-10-03
LU91381I2 (fr) 2008-01-30
JP2011212020A (ja) 2011-10-27
NL300307I1 (nl) 2008-02-01
DE19612967A1 (de) 1997-10-02
PT1526172E (pt) 2011-09-01
JP2010275321A (ja) 2010-12-09
JP5264843B2 (ja) 2013-08-14
ES2367081T3 (es) 2011-10-28
EP0891420B2 (de) 2013-11-20
ES2435726T3 (es) 2013-12-23
US20030119183A1 (en) 2003-06-26
EP0891420B1 (de) 2005-02-02
CA2250078C (en) 2009-06-23
CA2250078A1 (en) 1997-10-09
DK0891420T3 (da) 2005-04-25
DE69732407T3 (de) 2014-07-10
EP1526172A1 (de) 2005-04-27
JP4447054B2 (ja) 2010-04-07
DK0891420T4 (da) 2014-01-20
EP2172543B1 (de) 2013-08-21
EP2172543A1 (de) 2010-04-07
EP0891420A1 (de) 1999-01-20
DE122007000082I1 (de) 2009-01-02
HK1142093A1 (en) 2010-11-26
JP2006296437A (ja) 2006-11-02
ES2236799T5 (es) 2014-01-23
HK1075467A1 (en) 2005-12-16
PT891420E (pt) 2005-06-30
JP2000507825A (ja) 2000-06-27
EP1526172B1 (de) 2011-06-22
JP2013116124A (ja) 2013-06-13
DE69732407T2 (de) 2006-01-19
US20070117131A1 (en) 2007-05-24

Similar Documents

Publication Publication Date Title
ATE513905T1 (de) Verfahren für die replikation von influenza in zellkultur, und die bei diesem verfahren hergestellten influenza viren
DE69740002D1 (de) Tierzellen und verfahren für die replikation von influenza viren
DE69111440D1 (de) Methoden und zusammensetzungen zur impfung gegen hiv.
DE69939312D1 (de) Verfahren zur identifizierung von induktoren und inhibitoren proteolytischer antikörper, zusammensetzungen sowie deren verwendungen
ATE481480T1 (de) Methoden und zusammensetzungen zur herstellung von polypeptiden
DK0922102T3 (da) Receptor-agonister af hepatocyt-vækstfaktor og anvendelser deraf
DE69624789D1 (de) Verfahren zur herstellung von makrophagen und ausrüstungen zur durchführung dieses verfahrens
DE69532137D1 (de) Verbessertes verfahren zur stabilisierung biologischer substanzen während der trocknung und anschliessender lagerung sowie die entsprechenden zusammensetzungen
ATE264717T1 (de) Mikrofluidisches system und verfahren zu dessen betrieb
DE3585953D1 (de) Dna-fragmente, expressionsvektoren, proteine, wirte und verfahren zur herstellung der proteine.
SE8205244D0 (sv) Medel for avlegsnande av mikroorganismer fran vevnader
DE69005987D1 (de) Dichtung, Vorrichtung und Verfahren zur ihrer Herstellung.
DE3877711D1 (de) Antibeschlagzusammensetzung, damit beschichtetes produkt und verfahren zu dessen herstellung.
DE68923171D1 (de) Aluminiumhydroxyd, verfahren zur herstellung und zusammensetzung.
ATE254137T1 (de) ßLIGAND PRESENTING ASSEMBLYß (LPA), VERFAHREN ZU DESSEN HERSTELLUNG UND VERWENDUNGEN
DE69632472D1 (de) Verfahren und zusammensetzung zur herstellung von austrocknungstoleranten sporen von paecitomyces fumosoroseus
DE69013132D1 (de) Verfahren zur Herstellung von Octa-2,7-dien-1-ol.
KR950700988A (ko) 미생물, 이들의 제조방법 및 이들의 사용(Micro-organisms, preparation method therefor and uses thereof)
DE59001813D1 (de) Verfahren zum fertigen von werkstuecken, insbesondere von fahrzeug-antriebsaggregaten, sowie einrichtung zur durchfuehrung des verfahrens.
ATE231486T1 (de) Optisch aktive 2-amino-tetraline, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen die diese enthalten und die nützlich sind zur vorbeugung und behandlung von septischem schock
LU78800A1 (de) Verfahren zur behandlung fremd-bzw.schadstoffbeladener gasgemische,wie insbesondere luft
AT346797B (de) Verfahren zur herstellung von blechen, insbesondere von grobblechen, und einrichtung zur durchfuehrung des verfahrens
ATE34386T1 (de) 1,2,3,4-tetrahydro-1-aminomethyl-4-phenylisochinoline und verfahren zu ihrer herstellung.
DE3872648D1 (de) Alkanoylesterverbindungen, zwischenverbindungen dazu und verfahren zur herstellung.
DE69008488D1 (de) Verfahren zur Herstellung von N-Alkylaminophenolen und von N,N-Dialkylaminophenolen.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1526172

Country of ref document: EP